• Chairman & CEO

    Dr Mel Bridges

    Mel has over 30 years' experience building successful, international lifescience, diagnostic and medical device companies and commercialising a wide range of Australian technology. He holds a Bachelor of Science and a Doctorate from the Queensland University of Technology. Mel is also a Fellow of the Australian Institute of Company Directors (AICD) and is also on their Council. Mel is responsible for numerous commercial and M&A transactions and liquidity events exceeding $1 billion. He has raised over $400 million in biotech investment capital.

    Mel has received numerous prestigious national and state business awards including the 2005 AusBiotech Chairman’s Industry Medal and 2004 Queensland Entrepreneur of the Year. Mel has successfully founded and exited veterinary and human lifescience companies, including the recent sale of Peptech Animal Health to Virbac in 2011, and Catapult Genetics to Pfizer Animal Health in 2008.

    Mel is currently a director of ASX100 company ALS Ltd (ASX:ALQ) , and Chairman and Non-Executive Director of Oventus Medical Ltd (ASX:OVN).
  • Chief Scientific Officer

    Dr Tracey Mynott

    Tracey is one of the inventors of the Detach® technology, being involved with its development in the 1990s, and more recently with the development of the new formulation.

    Tracey has a PhD in the pathogenesis of enteric infections with a particular focus on the Detach® concept and enterotoxigenic E. coli infections. She has conducted post-doctoral studies at The Center for Vaccine Development at the University of Maryland in USA, the Division of Gastroenterology within The Royal College of Physicians and Surgeons at Columbia University in New York, the Digestive Diseases Research Centre at the Medical College of St Bartholomew''s Hospital in London and in the Department of Biochemistry, Imperial College in London.

    Tracey is the former Head of Business Development at the Queensland Institute of Medical Research, one of Australia''s most prestigious research organisationss. She has also held senior management positions in public and private Australian and UK biotechnology companies, where she has successfully discovered and patented several technologies, devised and directed drug development and clinical programs, developed and implemented business strategies, including licensing, acquisitions, capital raising and marketing.
  • Chief Operating Officer

    Dr Michael West

    Michael completed a Ph.D. in Organic Chemistry from James Cook University in 1990. Following his Ph.D. studies he worked at Smithkline Beecham pharmaceuticals in King of Prussia, before relocating to Brisbane and working in the Centre for Drug Design & Development at the University of Queensland. Since 1995, Michael has consulted to a number of Companies and organization, and has served on the Pharmaceutical Subcommittee – an advisory subcommittee to the Australian drug evaluation committee at the Therapeutic Goods Administration.

    Michael Joined Alchemia Limited in 1997, and was responsible for the manufacturing development and execution for fondaparinux sodium, Alchemia’s synthetic heparin product. Michael was also responsible for the scale-up and manufacture of all of Alchemia’s developmental products.

    Michael was awarded a Masters in Industrial Property from the University of Technology Sydney, and is a registered Patent & Trade Mark Attorney. He is the founder or MoJo Biotechnology and holds an adjunct associate Professorship with the Department of Chemistry, The University of Queensland.
  • Chief Development Officer

    Dr Tracey Brown

    Tracey joined Anatara in September 2016 where she is responsible for the direction and management of the human product development program.

    After obtaining her PhD in Biochemistry from Monash University, Tracey worked in academic and commercial research institutions in the USA, Europe and Australia where she focused on developing products for the treatment of cancer, inflammation and anti-aging.

    Over the last 20 years, Tracey has built, managed and lead international product development teams which have taken products from conception through to registration. Through this process, Tracey has developed extensive experience in the identification and evaluation of suitable commercialisation assets, manufacture of chemical and biological therapeutics, development and implementation of preclinical and clinical development plans, clinical program management, regulatory affairs, interaction with international regulatory agencies and product reimbursement processes.

    Prior to joining Anatara, Tracey was a co-founder of the ASX-listed company, Meditech; the Chief Scientific Officer of Alchemia and has acted as a director on the board of both listed and private biotechnology companies. Tracey also holds an adjunct Associate Professorship at Monash University where she participates in the commercialisation of research and the mentoring of academic researchers to assist in their transition into the biotechnology industry.
  • Head of Global Business Development

    Damian Wilson

    Damian has more than 25 years Australian & international experience in senior management positions within the agribusiness sector. He has significant experience in the animal health and veterinary pharmaceutical markets across more than 20 countries as well as Australia.

    His career in building businesses extends from start-up ventures to turnaround enterprises and large global private company roles. These include Norbrook Laboratories Asia Pacific and Middle East region, Coopers Animal Health, Smorgon Consolidated Industries, J Wright & sons as well as external consulting roles to companies in export development and distribution within the animal health and agribusiness industry globally. Damian’s track record includes establishing subsidiary companies in Australia & New Zealand developing and implementing distribution contracts in Asia, Europe, America & Africa.

    Damian holds a post graduate diploma in Agribusiness from the Monash University Melbourne Australia.
  • Operations Manager

    Dr Carla Baldwin

    Carla holds a BSc (Hons) in Genetics and a PhD in Quantitative Pathology from the Centre for Cancer Research at Queens University of Belfast, UK. She worked as a Post Doctoral Research Fellow for four years in 2D and 3D quantitative imaging in prostate cancer at Queens University, and continued her Research Fellow experience, managing a diverse research team at the National Centre for Adult Stem Cell Research at Griffith University.

    As a commercialisation officer at IMBcom, her role was to manage the development of innovative research and advance the outputs to successful commercialisation. She also project managed a highly commercial bio-fuels research pilot plant. As the Research Manager at the Queensland Emergency Medicine Research Foundation, Carla administered a multi-million dollar annual research funding program.
  • Commercial Manager

    Hayley van der Meer

    Hayley has extensive experience in the medical diagnostics and agricultural biotechnology industries, holding positions in both Australia and the USA with ASX listed diagnostics manufacturer, Panbio Limited, the former Molecular Plant Breeding Cooperative Research Centre (MPB CRC), and most recently with ASX listed Leaf Energy Ltd. Hayley specialises in sales and marketing, communications, public relations/investor relations, commercialisation of new technology, technology transfer, intellectual property management and project management.

    Hayley holds a Bachelor of Biomedical Science from Griffith University and a Graduate Diploma in Marketing Management from Central Queensland University.
  • Group Accountant

    Alan Dowling

    Alan completed his BBus at the University of Southern Queensland and spent his early career in private accountancy firms before moving to PwC where he worked in private and commercial tax.

    Alan has owned and managed a number of successful private companies before moving to Anatara as Group Accountant.
  • Clinical Trials Manager

    Kylie Davis

    Kylie is responsible for facilitating the implementation and management of clinical trial activity conducted by Anatara.

    She has over 16 years working in the veterinary industry, with almost 10 years working as a Senior Clinical Research Associate for Zoetis (formerly Pfizer Animal Health) the world’s largest producer of medicine and vaccines for animals. Kylie has coordinated and supported clinical trials in Australia and overseas, ensuring they were conducted in compliance with appropriate regulations and within the set time frame and budget.

    Kylie holds a certificate IV in Veterinary Nursing and Advanced Diploma of Business from Swinburne University of Technology.
  • Analytical Services Manager

    Dr Gareth Chadwick

    Gareth gained his PhD in Analytical Chemistry from the University of Strathclyde in Glasgow, and has over 18 years’ experience in pharmaceutical research and development.

    Gareth has a broad analytical background, spanning all phases of drug discovery, development and manufacture. He has worked at organisations ranging from global big pharma through contract development organisations to focussed biopharmaceutical companies.

    Gareth has extensive experience of method development, validation and control for small molecule and protein analyses, and has been involved in the development and registration of numerous new medicines.
  • International Regulatory Affairs Advisor

    Dr Kevin Woodward

    Dr Woodward has significant scientific expertise and animal health leadership experience with former roles including Director of Global Pharmacovigilence for Intervet/Schering Plough Animal Health. Dr Woodward was also responsible for all aspects, scientific and administrative, within the Veterinary Medicines Directorate, and liaison with the Medicines and Healthcare products Regulatory Agency (MHRA), with other European veterinary regulatory agencies and with the European Medicines Agency.

    He has been a member of the Committee for Medicinal Products for Veterinary Use (CVMP), chairman of its Safety of Residues Working Party, and a member of the Joint FAO/WHO Expert Committee on Food Additives (JECFA). He has also been a delegate to the Codex Committee on Residues of Veterinary Drugs in Foods.

    Dr Woodward is a Fellow of the Royal College of Pathologists and a Fellow of several other prestigious Colleges, and is a Member of the European Association for Veterinary Pharmacology and Toxicology (EAVPT).